Thursday, June 17, 2010 
ARIKACE™ DEMONSTRATES SUSTAINED BENEFIT IN THE TREATMENT OF CYSTIC FIBROSIS PATIENTS WHO HAVE PSEUDOMONAS LUNG INFECTIONS

Monday, May 24, 2010 
TRANSAVE ISSUED KEY COMPOSITION OF MATTER PATENT FOR ARIKACE™

Saturday, October 17, 2009 
TRANSAVE COMPLETES SUCCESSFUL PHASE II CLINICAL PROGRAM FOR ARIKACE™ IN THE TREATMENT OF PSEUDOMONAS LUNG INFECTIONS

Sunday, September 13, 2009 
TRANSAVE ANNOUNCES POSITIVE PHASE II RESULTS FOR ONCE-DAILY ARIKACE™ IN THE TREATMENT OF NON-CF BRONCHIECTASIS PATIENTS WHO HAVE PSEUDOMONAS LUNG INFECTIONS

Thursday, July 30, 2009 
TRANSAVE ENTERS INTO COOPERATIVE RESEARCH AGREEMENT WITH NIH TO STUDY ARIKACE™ IN NONTUBERCULOUS MYCOBACTERIA

Thursday, June 25, 2009 
TRANSAVE RECEIVES $2.2 MILLION CYSTIC FIBROSIS FOUNDATION AWARD FOR DEVELOPMENT OF ARIKACE™

Tuesday, April 21, 2009 
TRANSAVE COMPLETES ENROLLMENT IN ARIKACE™ PHASE II BRONCHIECTASIS STUDY

Thursday, October 02, 2008 
TRANSAVE, INC. SECURES $12.5 MILLION IN NEW FINANCING

Friday, June 13, 2008 
TRANSAVE ANNOUNCES POSITIVE PHASE II RESULTS FOR ONCE-DAILY ARIKACE™ IN THE TREATMENT OF CYSTIC FIBROSIS PATIENTS WHO HAVE PSEUDOMONAS LUNG INFECTIONS

Monday, March 31, 2008 
STUDY CONFIRMS ANTI-INFECTIVE ARIKACE™ EFFECTIVELY PENETRATES MUCUS AND BIOFILM, AND KILLS PSEUDOMONAS, A BACTERIA PLAGUING CYSTIC FIBROSIS PATIENTS

Monday, March 31, 2008 
TRANSAVE, INC. RAISES $35 MILLION THROUGH SERIES D CONVERTIBLE PREFERRED STOCK FINANCING

Tuesday, June 26, 2007 
TRANSAVE, INC. ANNOUNCES APPOINTMENT OF NICHOLAS GURRERI AS SENIOR VICE PRESIDENT OF COMMERICAL OPERATIONS AND BUSINESS DEVELOPMENT

Monday, June 04, 2007 
TRANSAVE, INC. REPORTS PROMISING DATA FROM A PHASE I/II TRIAL OF SLIT™ CISPLATIN IN PATIENTS WITH OSTEOSARCOMA METASTATIC TO THE LUNG

Friday, May 11, 2007 
TRANSAVE, INC. APPOINTS MICH SOGA AS CHIEF FINANCIAL OFFICER

Monday, October 02, 2006 
TRANSAVE, INC. APPOINTS RENU GUPTA, M.D. CHIEF MEDICAL OFFICER

Wednesday, August 02, 2006 
TRANSAVE’S SLIT™ AMIKACIN IS GRANTED ORPHAN DRUG DESIGNATION BY THE EUROPEAN COMMISSION FOR THE TREATMENT OF PSEUDOMONAS AERUGINOSA LUNG INFECTIONS IN CYSTIC FIBROSIS

Monday, June 19, 2006 
TRANSAVE, INC. APPOINTS TIMOTHY G. WHITTEN PRESIDENT AND CHIEF EXECUTIVE OFFICER

Friday, April 28, 2006 
TRANSAVE, INC. APPOINTS DONALD HAYDEN, JR.EXECUTIVE CHAIRMAN OF ITS BOARD OF DIRECTORS

Thursday, March 23, 2006 
TRANSAVE RECEIVES ORPHAN DRUG DESIGNATION FROM THE FDA FOR SLIT™ AMIKACIN FOR TREATMENT OF PULMONARY PSEUDOMONAS AERUGINOSA INFECTIONS IN CYSTIC FIBROSIS PATIENTS